Quick Answer: Psilocybin-assisted therapy for anxiety is still experimental in Canada and generally only available through clinical trials or Health Canada's Special Access Program. Early research from Canadian and international groups suggests possible benefits, but it is not a routine treatment. Talk with your doctor before considering any psychedelic therapy.
In This Guide
Reading Time: 7 minutes
Interest in psilocybin's therapeutic potential has moved from fringe to mainstream research in a relatively short time. Health Canada's Special Access Program for psilocybin has allowed a small number of Canadians to access it outside of clinical trials since 2020, and research institutions across Canada have been building clinical trial infrastructure. Queen's University and Kingston Health Sciences Centre have been part of this research expansion.
One of the outcomes being examined in these trials is sleep quality, particularly in patients receiving psilocybin for anxiety or depression. The connection between anxiety and insomnia is well-established, and if psilocybin reduces anxiety, the downstream effect on sleep is a natural secondary question.
This article explains what is known, what is not yet known, and what is available to Ontario residents now versus what may become available as research matures.
The Psilocybin-Anxiety-Sleep Connection
Anxiety and sleep disturbance have a bidirectional relationship: anxiety worsens sleep quality, and poor sleep increases anxiety. This cycle is a major obstacle in treating either condition independently. Hyperarousal, the physiological and cognitive activation state that characterises anxiety, directly opposes the relaxation needed for sleep onset. Cognitive rumination and worry at bedtime are common presentations in both anxiety disorders and chronic insomnia.
Anxiety, Sleep, and the Default Mode Network
Psilocybin's proposed mechanism for reducing anxiety involves disruption of the default mode network (DMN), a brain network associated with self-referential thinking, rumination, and the "narrative self." Carhart-Harris et al. (2012) in Proceedings of the National Academy of Sciences found that psilocybin reduces DMN activity, which may explain the observed reduction in ruminative thinking following psilocybin sessions. For people with anxiety-related insomnia where bedtime rumination is a primary driver of sleeplessness, this mechanism is directly relevant. Whether this effect translates to meaningful improvement in sleep architecture (more deep NREM, improved sleep efficiency) is an open research question.
The hypothesis, then, is that psilocybin-assisted therapy might break the anxiety-insomnia cycle by addressing the hyperarousal and ruminative cognition that sustain both conditions. This is plausible based on mechanism but has not been confirmed in adequately powered sleep-specific clinical trials as of early 2026.
Canadian Research on Psilocybin and Sleep
Queen's University in Kingston has been involved in psychedelic research through the Queens Psychedelic Research Group and affiliated researchers. Kingston Health Sciences Centre, as Queen's primary teaching hospital affiliate, has been part of the institutional infrastructure supporting this research.
Canadian psilocybin research relevant to sleep and anxiety includes:
The Psilocybin for Anxiety in Cancer Patients trial (various sites including Kingston-area investigators) examined psilocybin-assisted therapy for existential anxiety in people with serious illness. Sleep quality was among the secondary outcomes measured. Early results from similar trials at Johns Hopkins and NYU showed improvements in self-reported sleep quality, but Canadian results have not yet been published in peer-reviewed form as of early 2026.
Health Canada granted expanded Special Access Program (SAP) access to psilocybin in 2023, allowing individual patients with treatment-resistant conditions to apply for access outside of formal trials. A small number of Canadians have received psilocybin through this pathway for treatment-resistant depression and PTSD, with anxiety and sleep as frequent secondary targets.
The Canadian Psychedelic Research Council has been tracking outcomes across SAP recipients and trial participants, with consolidated data expected in 2026-2027.
What the Evidence Actually Shows
Being honest about the current state of evidence is important here, because media coverage of psychedelic research is often ahead of the actual findings.
Psilocybin and Sleep: Current Evidence Status
- What is well-established: Psilocybin transiently suppresses REM sleep on the night of administration (Dudysova et al., 2020 in Frontiers in Pharmacology). This is a consistent pharmacological finding.
- What is preliminary but promising: Several trials report improved self-reported sleep quality in the weeks to months following a psilocybin session, beyond the acute night. This is observed in anxiety and depression studies as a secondary outcome, but these are not powered or designed to assess sleep specifically.
- What is not yet established: Whether the sleep improvements are directly caused by psilocybin's neurological effects or are a secondary consequence of anxiety/depression reduction. The two cannot be easily separated without specific sleep-focused trial design.
- What is actively being studied: Sleep architecture effects (objective measurement of sleep stages) following psilocybin therapy. Preliminary work at several institutions suggests possible increases in slow-wave (deep NREM) sleep in subsequent nights, which would be meaningful, but this needs replication.
The honest summary: the signal is interesting, the mechanism is plausible, and the preliminary observations are generally positive. The evidence is not yet at the level that would support recommending psilocybin as a sleep treatment, nor is it accessible as one in Ontario.
How to Access Psilocybin Research Trials in Canada
For Ontario residents interested in participating in psilocybin research:
Clinical trial registration is the primary pathway. Trials registered in Canada can be searched at ClinicalTrials.gov (which includes Canadian trials) using search terms like "psilocybin Ontario" or "psilocybin anxiety sleep." Eligibility criteria vary by trial and most have exclusion criteria for people with personal or family history of psychosis, certain medications (particularly SSRIs, which interact with psilocybin's serotonergic mechanism), and comorbid conditions.
Health Canada Special Access Program (SAP): Patients with treatment-resistant anxiety, depression, or PTSD can apply through a licensed healthcare provider for psilocybin access under the SAP. This requires a psychiatrist or physician to submit the application on the patient's behalf. The SAP is not a treatment program; it is a regulatory mechanism for accessing a controlled substance for individual patient use under medical supervision.
Private psilocybin-assisted therapy is not legally available in Ontario outside of research or SAP contexts as of early 2026. Individuals or clinics offering psilocybin therapy outside these frameworks are operating illegally. Health Canada's SAP approval is the legitimate pathway for individuals.
Psychedelic Research Proximity to Brantford
Queen's University in Kingston is approximately 2.5-3 hours from Brantford by car. For Brantford residents interested in participating in clinical trials at Kingston, this distance may be a practical barrier depending on the trial's visit schedule. McMaster University in Hamilton, which is closer to Brantford (approximately 45 minutes), has also been developing psychedelic research programs through the Psychedelic Research Initiative. Local family physicians in Brantford can provide referrals and, if appropriate, support SAP applications for patients meeting eligibility criteria. Anyone interested should discuss this with their family doctor rather than attempting to access psilocybin through unregulated channels.
8 min read
Current Anxiety and Sleep Treatment Options in Ontario
While psilocybin research develops, Ontario residents with anxiety-related sleep disorders have access to established treatments that are effective and available now:
CBT-I (Cognitive Behavioural Therapy for Insomnia) addresses the cognitive and behavioural patterns that sustain insomnia, including anxiety-driven hyperarousal at bedtime. As described in our related article on the Queen's University model, CBT-I is the evidence-based first-line treatment for chronic insomnia.
CBT for anxiety disorders (CBT-A) addresses the anxiety component through structured therapy available through the Ontario Structured Psychotherapy (OSP) program, some community mental health centres, and private psychologists.
Pharmacological options for anxiety-related insomnia include SSRIs or SNRIs prescribed by a physician, and short-term sleep medications used judiciously. Long-term benzodiazepine use is generally considered problematic due to dependence and tolerance issues.
Acceptance and Commitment Therapy (ACT) and mindfulness-based stress reduction (MBSR) have evidence for both anxiety and insomnia. Both are available through psychologists and some group programs in Ontario.
The Mattress and Anxiety-Related Sleep Problems
We want to be clear: a mattress does not treat anxiety. But anxiety-related insomnia has both psychological and environmental components, and addressing the environmental components creates better conditions for psychological treatment to work.
Temperature dysregulation is common in people with anxiety. Elevated cortisol from anxiety can increase body temperature and make heat regulation harder during sleep. A mattress that traps heat compounds this. Our Restonic Luxury Silk and Wool model at $1,395 uses natural wool for temperature regulation, which handles moisture better than synthetic foams. Wool absorbs and releases moisture without feeling wet, maintaining a more stable microclimate across the night.
Pressure sensitivity can also be heightened when sleep architecture is disrupted by anxiety. Someone waking frequently in light sleep stages feels pressure points more acutely than someone in deep NREM. A mattress with adequate pressure relief (achieved through targeted contouring foam or zoned support coils) reduces the physical discomfort signal that contributes to wake events. Talia, our showroom specialist, often works with customers dealing with anxiety-related sleep issues and finds that temperature and pressure are the two physical factors most frequently mentioned alongside the psychological components.
Shop: King Mattresses at Mattress Miracle
Shop This Topic at Mattress Miracle
Popular picks at Mattress Miracle:
Or shop the full mattress lineup in our Brantford showroom.
Find Your Perfect Mattress at Mattress Miracle
We are a family-owned mattress store in Brantford, helping our community sleep better since 1997. Come try mattresses in person and get honest, no-pressure advice.
441 1/2 West Street, Brantford, Ontario
Call 519-770-0001Frequently Asked Questions
Is psilocybin legal in Canada for treating anxiety or insomnia?
Psilocybin remains a Schedule III controlled substance in Canada. It is not a legal treatment available through Ontario's healthcare system. Access is only through Health Canada's Special Access Program (for individuals with treatment-resistant conditions, through a physician) or through formally registered clinical trials. Anyone claiming to offer psilocybin therapy outside these channels is operating illegally in Canada. If you are interested in this treatment, discuss it with your family physician who can advise on SAP eligibility or trial participation.
Does psilocybin affect sleep quality on the night it is taken?
Yes, and the effect is generally disruptive on the night of administration. Psilocybin suppresses REM sleep acutely, and the experience itself (which lasts 4-6 hours) is incompatible with normal sleep architecture. Psilocybin therapy sessions are typically conducted during the day, not at bedtime. The proposed benefit to sleep comes from changes in anxiety and neuroplasticity that develop over subsequent days and weeks, not from any hypnotic effect on the night taken.
Are there risks to psilocybin therapy for anxiety and sleep?
Yes. Psilocybin is contraindicated for people with personal or family history of psychosis or schizophrenia spectrum disorders. It has significant interactions with serotonergic medications including SSRIs. The therapy context (set and setting, therapist support) is considered critical to safety and outcomes; psilocybin used unsupervised in uncontrolled settings has a different risk profile than supervised clinical therapy. Reputable clinical trials include rigorous screening and supervision to manage these risks. This is why accessing psilocybin only through approved channels is important.
Where can I find Canadian psilocybin clinical trials accepting participants?
Search ClinicalTrials.gov using "psilocybin Canada" or "psilocybin Ontario" to find currently recruiting trials. The Canadian Psychedelic Research Council website also maintains information about Canadian research initiatives. Some trials are open to participants across Canada through telehealth screening followed by on-site sessions; proximity to the research institution (Kingston, Hamilton, Toronto, Vancouver) is typically required for in-person sessions.
Is there anything I can do now for anxiety-related insomnia while research develops?
Yes, and the evidence base for current treatments is strong. CBT-I combined with CBT for anxiety has the best evidence for the anxiety-insomnia combination. Discuss referral options with your family physician; telehealth psychotherapy has expanded access significantly since 2020. Sleep hygiene optimisation (temperature, light, consistent schedule) addresses environmental factors. If physical discomfort from an old mattress is adding to nighttime wakefulness, addressing that is a practical step. Call Mattress Miracle at (519) 770-0001 or visit us at 441 1/2 West Street, Brantford.
Sources
- Carhart-Harris, R.L., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143. doi.org/10.1073/pnas.1119598109
- Dudysova, D., et al. (2020). The effects of daytime psilocybin administration on sleep: Implications for antidepressant action. Frontiers in Pharmacology, 11, 602590. doi.org/10.3389/fphar.2020.602590
- Buysse, D.J. (2014). Sleep health: Can we define it? Does it matter? Sleep, 37(1), 9-17. doi.org/10.5665/sleep.3298
- Health Canada. (2023). Special Access Program: Psilocybin regulations and procedures. Government of Canada. canada.ca
- Okamoto-Mizuno, K., & Mizuno, K. (2012). Effects of thermal environment on sleep and circadian rhythm. Journal of Physiological Anthropology, 31(1), 14. doi.org/10.1186/1880-6805-31-14
- Morin, C.M., et al. (2006). Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998-2004). Sleep, 29(11), 1398-1414. doi.org/10.1093/sleep/29.11.1398
Visit Our Brantford Showroom
We are located at 441½ West Street in downtown Brantford. Free parking available. Our team does not work on commission, so you get honest advice based on your needs.
Mattress Miracle , 441½ West Street, Brantford, ON · (519) 770-0001
Hours: Monday-Wednesday 10am-6pm, Thursday-Friday 10am-7pm, Saturday 10am-5pm, Sunday 12pm-4pm.